Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 241

The DOI matches its Crossref record.

Committee Opinion No. 690: Carrier Screening in the Age of Genomic Medicine

·2017·Obstetrics & Gynecology

Abstract

Recommendations Ethnic-specific, panethnic, and expanded carrier screening are acceptable strategies for prepregnancy and prenatal carrier screening. Each obstetrician–gynecologist or other health care provider or practice should establish a standard approach that is con-sistently offered to and discussed with each patient, ideally before pregnancy. After counseling, a patient may decline any or all carrier screening. If a patient requests a screening strategy other than the one used by the obstetrician–gynecologist or other health care provider, the requested test should be made available to her after counseling on its limitations, benefits, and alternatives. All patients who are considering pregnancy or are already pregnant, regardless of screening strategy and ethnicity, should be offered carrier screening for cystic fibrosis and spinal muscular atrophy, as well as a complete blood count and screening for thalassemias and hemoglobinopathies. Fragile X premutation carrier screening is recommended for women with a family history of fragile X-related disorders or intellectual disability suggestive of fragile X syndrome, or women with a personal history of ovarian insufficiency. Additional screening also may be indicated based on family history or specific ethnicity. Couples with consanguinity should be offered genetic counseling to discuss the increased risk of recessive conditions being expressed in their offspring and the limitations and benefits of carrier screening. Carrier screening will not identify all individuals who are at risk of the screened conditions. Patients should be counseled regarding residual risk with any test result. Prenatal carrier screening does not replace newborn screening, nor does newborn screening diminish the potential benefit of prenatal carrier screening. If a woman is found to be a carrier for a specific condition, her reproductive partner should be offered screening to provide accurate genetic counseling for the couple with regard to the risk of having an affected child. Additional genetic counseling should be provided to discuss the specific condition, residual risk, and options for prenatal testing. If a carrier couple (ie, carriers for the same condition) is identified before pregnancy, genetic counseling is encouraged so that reproductive options (eg, donor gametes, preimplantation genetic diagnosis, prenatal diagnosis) can be discussed. Individuals with a family history of a genetic disorder may benefit from the identification of the specific familial mutation or mutations rather than carrier screening. Knowledge of the specific familial mutation may allow for more specific and rapid prenatal diagnosis. Given the multitude of conditions that can be included in expanded carrier screening panels, the disorders selected for inclusion should meet several of the following consensus-determined criteria: have a carrier frequency of 1 in 100 or greater, have a well-defined phenotype, have a detrimental effect on quality of life, cause cognitive or physical impairment, require surgical or medical intervention, or have an onset early in life. Additionally, screened conditions should be able to be diagnosed prenatally and may afford opportunities for antenatal intervention to improve perinatal outcomes, changes to delivery management to optimize newborn and infant outcomes, and education of the parents about special care needs after birth. Carrier screening panels should not include conditions primarily associated with a disease of adult onset. Introduction Carrier screening is a term used to describe genetic testing performed on an asymptomatic individual to determine whether that person has a mutation or abnormal allele within a gene that is associated with a particular disorder. Carrier screening can be performed for one specific condition or for multiple disorders. The likelihood of identifying someone as a carrier for an inherited genetic condition reflects the prevalence of the condition in a particular population. In the absence of a family history, the more prevalent a condition the greater the likelihood of finding a carrier. This fact has historically guided practitioners to offer genetic screening to those individuals at highest risk of carrying particular disorders based on the individual’s race, ethnicity, or family history. Traditionally, carrier screening was targeted toward specific ethnic populations known to be at increased risk of particular disorders, commonly known as ethnic-based screening, such as screening those of Ashkenazi Jewish descent for Tay–Sachs disease. However, in the present multiracial society, it is increasingly difficult to define an individual’s ancestry. Therefore, the pretest probability of being a carrier for a specific disorder may not be consistent with previous assumptions about the prevalence of that disorder in the various ethnic and racial groups with which a patient identifies (1). In addition, particular disorders are less likely

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/aog.0000000000001951

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 241

Metadata

Venue
Obstetrics & Gynecology
Published
2017-03
Volume
129
Issue
3
Pages
e35-e40
ISSN
0029-7844 (ISSN-L)
OpenAlex
W4235160721
Cited by
241
References
0
FWCI
21.93
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Committee Opinion No. 690: Carrier Screening in the Age of Genomic Medicine. https://app.cochat.ai/papers/10.1097/aog.0000000000001951
The paper
Committee Opinion No. 690: Carrier Screening in the Age of Genomic Medicine. (2017). Obstetrics & Gynecology. https://doi.org/10.1097/aog.0000000000001951

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.